Navigation Links
Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
Date:1/9/2012

GENEVA, Jan. 9, 2012 /PRNewswire/ -- Selexis SA announced today the appointment of Yemi Onakunle, Ph.D., M.B.A. as Vice President of Strategic and Market Development.

Dr. Onakunle will report directly to President and CEO, Dr. Igor Fisch and will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets.

"Selexis is experiencing a tremendous growth cycle by offering more innovation and long-term value to our customers. Yemi's wealth of business development and sales experience in biologics and cell line development will be instrumental in expanding the SUREtechnology Platform™ into important markets," said Dr. Igor Fisch, CEO of Selexis. "Yemi's understanding of our technology and expanding global customer base makes him an excellent choice for this newly created position."

Dr. Onakunle has over 15 years' experience in drug manufacturing and cell line development. Prior to working at Selexis, Dr. Onakunle was Director of Commercial Development at Diosynth RTP Inc. and Associate Director of Business Development at Lonza Custom Manufacturing – organizations providing process development and cGMP manufacturing services in mammalian production platforms. More recently, Dr. Onakunle was Head of Sales and Marketing at Bachem Americas Inc. - a contract manufacturing organization focusing on peptides and complex organic molecules. In these positions, he has a strong record of consistently growing the customer base and sales and expanding product offerings into new markets. Dr. Onakunle is a member of the Board of Directors of VLP Biotech Inc, a vaccine development company based in San Diego, CA and has been a Business Advisor to several biopharmaceutical and drug delivery companies. Educated in the UK, Dr. Onakunle holds a Ph.D. from the University of Kent at Canterbury and an M.B.A. from Imperial College Management School.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information, visit http://www.selexis.com

Media Contact:

Robert Meister
robert.meister(at)selexis(dot)com
(602) 953-1716


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
7. CSL Limited Signs Commercial License Agreement with Selexis SA
8. Selexis SA to Present at Biotech Showcase 2012
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Omeros Appoints David A. Mann to its Board of Directors
11. RainDance Technologies Appoints Olex Vice President, System Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... Maryalnd (PRWEB) , ... July 13, 2017 , ... ... Innovative Technology Center, Inc. (FITCI), has experienced robust growth in the past year ... public/private nonprofit has launched several Entrepreneurial Acceleration Programs and expanded its board of ...
(Date:7/13/2017)... WA (PRWEB) , ... July 13, 2017 , ... ... machine vision solutions for life sciences, will demonstrate advancements of the MicroHAWK platform for ... systems – from Booth #4456 at the AACC Clinical Lab Expo, taking place on ...
(Date:7/12/2017)... ... July 12, 2017 , ... Dr. Julia Oh, a highly respected ... of a Microbiome Impact Grant from uBiome, the leading microbial genomics company. Dr. Oh ... in the transmission of pathogens between elderly people in geriatric communities. , The ...
(Date:7/11/2017)... ... ... The Pittcon Exposition Committee is now accepting booth space reservations for Pittcon 2018, ... for a standard 10’ x 10’ space is available to all exhibitors until September ... wish to be included in the first round of booth assignments should have their ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):